analysis of texts · NPJ digital medicine · la publicación, 28 may 2026 · gratis
Noruega y la UE ya tienen su manual de nueve pasos para reutilizar expedientes médicos
Es una guía de orientación hecha con 16 leyes y documentos europeos. No es asesoría legal, no se ha probado todavía y no dice nada sobre las leyes de América Latina, Estados Unidos ni Canadá.
Versión breve · la versión detallada sigue, unos 7 min
Pregunte al chat de weeklyAI
Pregúnteme sobre la IA en su vida: le señalo las notas que weeklyAI ha publicado sobre el tema, esta semana y antes.
Las conversaciones se guardan mientras exista weeklyAI, para mejorar la publicación. Se responde en el idioma en que usted escribe.
- El estudio, de un vistazo
- Quiénes
- Documentos legales sobre reutilización de expedientes médicos en Noruega y la UE
- Cuántos
- dieciséis documentos
- Dónde
- Noruega y la Unión Europea
- Cuándo
- marzo de 2025 (entrada en vigor del reglamento europeo)
- Tipo de estudio
- review of studies
- Quién lo hizo
- Universidad Noruega de Ciencia y Tecnología, con un abogado en salud e inteligencia artificial
- El límite que importa
- No es asesoría legal, no se probó y no cubre las leyes de América Latina, Estados Unidos ni Canadá.
Cuando su país discuta quién puede reutilizar su expediente médico, fíjese en tres cosas: si existirá un organismo de acceso, si le pedirán su consentimiento o lo reemplazarán con una dispensa ética, y si el análisis tendrá que hacerse en una sala segura.
En marzo de 2025 entró en vigor el reglamento europeo del Espacio Europeo de Datos Sanitarios. Su idea es que los expedientes médicos se puedan usar para investigación, innovación, mejora de la calidad y estadísticas, más allá del cuidado para el que se recogieron. Noruega aplica ese reglamento por su acuerdo con la Unión Europea.
El reglamento reparte el trabajo. Un organismo nacional de acceso revisa las solicitudes. El trabajo aprobado debe hacerse dentro de un entorno seguro de procesamiento, una sala controlada donde solo salen resultados anónimos.
Entre los autores hay informáticos y un abogado especializado en salud e inteligencia artificial. Revisaron 16 leyes, reglamentos y guías de Noruega y de la UE. De ahí salieron nueve pasos con listas de tareas.
Los pasos van en orden: clasificar el proyecto; fijar la base legal y el consentimiento o una dispensa; obtener la aprobación ética antes de tocar los datos; firmar los acuerdos de acceso; cifrar y registrar los accesos; usar solo los datos necesarios; analizar dentro de la sala segura; auditar el cumplimiento; y al final borrar los datos y publicar solo resultados anónimos.
Los propios autores advierten que la guía es un punto de partida. No sustituye la asesoría legal o ética de cada caso.
Los mismos pasos, dicen los autores, se pueden adaptar a otros países de la UE y del Espacio Económico Europeo. Para eso hay que averiguar primero quién revisa la ética, quién autoriza el acceso, dónde está la sala segura y quién vigila el cumplimiento. Cada país lo organiza a su manera.
La guía se basa en las leyes de Noruega y de la Unión Europea, y se puede adaptar a otros países con cambios. No dice qué permiten ni qué exigen las leyes de Estados Unidos, Canadá o América Latina. Además, las reglas europeas todavía se están aplicando por etapas. Noruega ya usa salas seguras para analizar datos de salud, y la obligación europea de usarlas entrará en vigor más adelante. Son reglas en parte futuras.
Cuando su país discuta quién puede reutilizar su expediente médico, fíjese en tres cosas: si existirá un organismo de acceso, si le pedirán su consentimiento o lo reemplazarán con una dispensa ética, y si el análisis tendrá que hacerse en una sala segura.
Qué significa para usted
Cuando en su país se discuta quién puede reutilizar su expediente médico, conviene preguntar si habrá un organismo que revise las solicitudes y si el análisis tendrá que hacerse en una sala controlada. La guía noruega no dice nada sobre las leyes de México, Estados Unidos, Canadá ni el resto de América Latina, y todavía no se ha probado con investigadores ni pacientes.
Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2
Quién pagó: El estudio contó con el apoyo del Comité de Enlace entre la Autoridad Sanitaria Regional de Noruega Central y la Universidad Noruega de Ciencia y Tecnología (código de proyecto 30233), y el artículo indica que las entidades financiadoras no tuvieron ningún papel en el diseño, la recogida de datos, el análisis, la interpretación ni la redacción.
No tome esto como consejo médico profesional.
Versión detalladaLos pasajes copiados del artículo, las ilustraciones y cada fuente con cuánto leímos de ella · 1321 palabras · unos 7 minLeerla →Cerrar
Una guía noruega de nueve pasos para reutilizar expedientes clínicos: lo que dice y lo que todavía no puede decir
Dieciséis documentos legales convertidos en listas de verificación. El detalle está en quién autoriza, quién revisa la ética y dónde se procesan los datos.
Imagine un expediente clínico. Ahí está su diagnóstico, su tratamiento, sus medicamentos, sus resultados de laboratorio. Ese expediente se creó para atenderle. Reutilizarlo para otra cosa —investigar, mejorar un servicio, planear políticas, entrenar un programa de cómputo— es lo que los documentos llaman uso secundario, y es distinto del uso primario, que es la atención directa1.
Un equipo de la Universidad Noruega de Ciencia y Tecnología, con un abogado especializado en salud e inteligencia artificial, revisó dieciséis documentos: cinco europeos, uno internacional, siete leyes noruegas y tres guías noruegas, entre ellos el reglamento del Espacio Europeo de Datos de Salud. De ahí salió una guía de nueve pasos con listas de verificación: clasificar el proyecto, fijar la base legal, obtener aprobación ética, firmar acuerdos de acceso, asegurar la privacidad, minimizar los datos, analizar dentro de un entorno seguro, auditar y cerrar. El estudio no midió ningún resultado. No probó que la guía acelere trámites ni que reduzca riesgos.
El problema de fondo tiene cifras. La revisión recoge un estudio en el que veinte países de la Unión Europea, el 74 por ciento, reportan que entre el 80 y el 100 por ciento de su población puede consultar su expediente clínico por los servicios de acceso disponibles. La revisión recoge un estudio en el que, aun así, la reutilización de esos datos sigue siendo poco aprovechada2. Piense en un edificio lleno de archivos ordenados y una puerta cerrada con llave: el material existe, el permiso para usarlo es lo que falta.
La guía describe la maquinaria. La revisión recoge un estudio en el que una autoridad nacional de acceso a datos recibe las solicitudes y emite permisos3. La revisión recoge un estudio en el que un comité de ética revisa por su lado, y el permiso de datos solo se emite después de que existan las aprobaciones éticas exigidas4. La revisión recoge un estudio en el que el análisis ocurre en un entorno de procesamiento seguro: una sala controlada donde solo se pueden sacar resultados anónimos, con registro de accesos y control de exportaciones56. Lo curioso es que esa separación de papeles —quién autoriza, quién juzga la ética, quién vigila la sala— es justamente lo que un ciudadano puede exigir que exista en su propio país.
El texto también señala una tensión que cualquiera que haya firmado un consentimiento reconocerá. La revisión recoge un estudio en el que el consentimiento bajo la ley noruega de investigación en salud no equivale al consentimiento bajo el reglamento europeo de protección de datos: la primera permite un consentimiento amplio o aprobado por comité de ética, mientras el segundo exige uno específico, explícito y revocable7. Dos reglas, un mismo paciente, y la pregunta de cuál manda en cada caso.
Los propios autores anotan las asperezas. La revisión recoge un estudio en el que investigadores reportan variación en las prácticas de aprobación ética entre regiones y plazos largos, y en proyectos con varias sedes eso se vuelve un obstáculo8. La revisión recoge un estudio en el que cumplir puede implicar una carga: solicitud de permiso, evaluación de impacto, revisión legal, trabajo de ingeniería de datos; si las plataformas seguras limitan la flexibilidad metodológica, la experimentación se frena9. La revisión recoge un estudio en el que, sin apoyo, capacitación y financiamiento, los grupos pequeños de investigación quedan en desventaja frente a instituciones grandes con más cómputo y más especialistas10.
Hay un límite de tiempo que el lector debe tener presente. La revisión recoge un estudio en el que tanto las regulaciones como la infraestructura están en movimiento: el reglamento europeo de datos de salud y la ley europea de inteligencia artificial se aplican por fases o se adaptan en cada país, y algunas interpretaciones cambiarán conforme madure la práctica regulatoria11. El entorno seguro que el reglamento europeo exige aún no está implementado y su obligación se aplica más adelante; lo que existe hoy son plataformas nacionales de análisis que quizá puedan convertirse en él si cumplen las especificaciones técnicas.
Así lo lee weeklyAI: la guía no es un permiso, es un mapa de trámites. Y ese mapa tiene una utilidad que sus autores quizá no buscaban: nombra las preguntas que cualquier persona puede hacer. Cuando en su país se hable de reutilizar datos de salud, hay tres preguntas concretas: quién autoriza, quién revisa la ética y dónde se procesan los datos. Si nadie sabe responderlas, eso mismo dice mucho del estado de la discusión. Esta lectura se equivocaría si resultara que la mayoría de la gente, al oír "datos de salud reutilizados", solo quiere saber cómo funciona el trámite y no le importa quién vigila.
El reglamento europeo también reparte derechos hacia el paciente. La revisión recoge un estudio en el que, bajo ese marco, las personas ganan transparencia: pueden ver su información en portales y saber qué entidades consultaron sus registros12. La revisión recoge un estudio en el que se reconocen además el derecho a oponerse al uso secundario y los derechos de acceso, corrección y portabilidad de los datos de salud electrónicos13. Concesión justa al sistema: sin confianza pública sostenida, la reutilización no se sostiene. El punto es que esos derechos no caen del cielo; alguien tuvo que nombrarlos y escribirlos.
Para otros países europeos, los autores recomiendan leer la guía por equivalencia funcional, no por copia exacta: las funciones de autorización, ética y entorno seguro pueden estar repartidas entre organismos de acceso, comités acreditados, custodios de registros, oficinas de estadística o salas institucionales14. La revisión recoge un estudio en el que, más adelante esta década, se espera que las especificaciones técnicas y la acreditación de esas salas se estandaricen entre países15. Pasa lo mismo con el trámite de una visa: el principio es el mismo, los requisitos cambian de consulado en consulado.
weeklyAI también leyó que la guía se presenta como orientación temprana para planear un proyecto y coordinar su gobierno, no como sustituto de asesoría legal o ética para un caso concreto16. Eso importa para el lector de América Latina, Estados Unidos o Canadá: el artículo cubre Noruega y el espacio europeo, y no dice nada sobre lo que su propia ley permite o exige. No es una declaración de sus derechos. Es un modelo de qué preguntar.
Hay una escena que vale la pena tener en mente. En una sala segura, un equipo analiza expedientes que nunca vio en persona. El riesgo no es que alguien sea malvado; es que la distancia vuelva rutina lo que debería ser cuidado: revisar sesgos, minimizar datos, frenar un análisis por riesgo de reidentificación. Si participa en un proyecto así, pida que se nombre a quién protege cada control, no solo qué norma lo exige. Como ciudadano, pregunte a la autoridad de su país cómo verifica que quienes usan los datos piensan en personas concretas.
Y una última cosa que weeklyAI espera ver en la región. Los derechos nuevos rara vez llegan como leyes completas; primero existen como una carencia que alguien siente y reclama. Es probable que las reglas sobre reutilización de datos de salud lleguen a América Latina y Norteamérica como exigencias de pacientes y colectivos —saber quién consultó mi expediente, oponerme a cierto uso, pedir corrección— antes que como marcos administrativos completos. Esta lectura se equivocaría si los países adoptaran primero marcos de permisos y salas seguras por decisión administrativa o comercial, sin presión organizada, y funcionaran igual de bien.
El expediente clínico que abrió esta pieza sigue ahí, creado para atenderle. Lo que ahora puede hacer con él es preguntar, en su país y en su clínica, quién decide reutilizarlo y ante quién se reclama. ¿Sabe usted quién autoriza el uso de su expediente en el lugar donde vive?
De dónde sale cada dato de contexto, y cuánto leímos de cada documento
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Secondary use refers to the use of health records beyond the original collection purpose, such as research, quality improvement, and policy planning 3 , 7 , 25 . The primary use of health records is for direct patient care."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "The EU/EEA member states maintain extensive Electronic Health Records (EHR), with twenty EU member states (74%) reporting that 80–100% of their population can access their health records through the provided access services 2 . Yet secondary use remains underutilized 1 , 10 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Under the EHDS, an HDAB is the designated national authority responsible for receiving and assessing secondary-use applications and issuing data access permits (EHDS Arts. 55 - 57 )."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "The HDAB does not supersede national ethics committees; ethical review remains national. Data permits are therefore issued only after any ethically required approvals have been obtained, ensuring complementary but clearly separated responsibilities."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "An SPE is a controlled technical environment in which approved secondary-use data processing must take place under defined technical and organizational safeguards ( EHDS Art. 73 )."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Inside such environments, users operate under strict technical and organizational controls and may export only non-personal, anonymized outputs in accordance with the conditions defined in the data permit. SPE operators must implement safeguards including role-based access control, logging, monitoring, and export control mechanisms."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Consent under the HRA is not equivalent to consent under GDPR. There is a nuance in that, the HRA allows broad or ethics-approved consent, while GDPR requires specific, explicit, and revocable consent 34 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "But researchers often report variation in ethical approval practices across regions, prolonged timelines 35 , and for multi-site projects, it can be a barrier."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Researchers may experience a compliance overhead (e.g., data permit application to HDAB, DPIA, legal review, data-engineering effort) if secure platforms restrict methodological flexibility, which can slow experimentation or innovation."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Without sufficient support, training, and funding, smaller research groups risk being disadvantaged compared to large, well-resourced institutions (e.g., in terms of compute, proprietary applications, domain experts) 19 , 25 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Currently, both regulations and infrastructure remain in flux. Regulations relevant to secondary use, particularly the EHDS and the AI act, are undergoing phased application or national adaptation, and some interpretations may evolve as regulatory practice matures."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Under the EHDS, patients gain additional transparency regarding the right to view (e.g., patient portals or ‘MyHealth@EU’), know which entities accessed their records ( EHDS Arts. 3 - 8 , 11 ) 21 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "Note individuals’ rights under the EHDS, including the right to opt-out of secondary use ( EHDS Art. 71 ) and the right of access, correction, and portability of electronic health data ( EHDS Arts. 3 - 9 ) are operationalized and documented."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "For the guideline transferability to the EU/EEA, they should be interpreted in terms of functional equivalence rather than exact institutional replication. In other EU/EEA countries, the HDAB, ethics approval, and SAE/SPE functions may be distributed across national access bodies, accredited ethics committees, registry custodians, statistical offices, or institutional secure research environments."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "As ‘HealthData@EU’ is rolled out later this decade, national HDAB and SPE technical specifications and accreditation ( EHDS Art. 73(5) , 75 ) are expected to be standardized across borders 8 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - el artículo del que trata esta nota — el artículo completo — el pasaje: "The guideline is designed for project scoping, governance coordination, and early regulatory orientation, rather than as a substitute for case-specific legal or ethical advice."
Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2
Quién pagó: El estudio contó con el apoyo del Comité de Enlace entre la Autoridad Sanitaria Regional de Noruega Central y la Universidad Noruega de Ciencia y Tecnología (código de proyecto 30233), y el artículo indica que las entidades financiadoras no tuvieron ningún papel en el diseño, la recogida de datos, el análisis, la interpretación ni la redacción.
No tome esto como consejo médico profesional.
Los hallazgos de otros estudios que aquí se mencionan provienen de este documento; esos estudios no se consultaron uno por uno.
analysis of texts · NPJ digital medicine · the paper, 28 May 2026 · free
Nine Steps Before Anyone Reuses Your Medical Records
A team of legal and computing specialists read 16 laws and guides and built a checklist. It covers Norway and the EU only, and its secure rooms do not exist yet.
Short version · the longer version follows, about 7 min
Ask the weeklyAI chat
Ask me about AI in your life: I point you to the stories weeklyAI has published on it, this week and before.
Conversations are saved for as long as weeklyAI exists, to improve the publication. Answers come in the language you write in.
- The study at a glance
- Who
- Sixteen regulatory documents on reusing health records, read by legal and computing specialists
- How many
- 16 documents
- Where
- Norway and the EU/EEA
- When
- in force since March 2025 (the EU health data regulation)
- Kind of study
- analysis of what people did
- Who did it
- Norwegian University of Science and Technology, with a hospital and a purchasing body
- The limit that matters
- It measures no outcomes, is untested, and does not describe the rules where you live
The study cannot tell you the rules where you live.
Norway and the European Union want the same thing: for health records to be used again, beyond the visit that created them. Researchers could study them. Companies could train software on them. Hospitals could check their own quality. Planners could count and forecast. The European Health Data Space regulation, in force since March 2025, sets the frame for this across the EU and, through the EEA agreement, in Norway.
Under that regulation, a national access body reviews each request to reuse records. Approved work must run inside a Secure Processing Environment: a controlled digital room where the data stays, and only anonymized results may leave.
How does a hospital or a research team get there lawfully? A team of legal and computing specialists at the Norwegian University of Science and Technology, with a hospital and a purchasing body, went looking. They read 16 documents: five from the EU, one international, seven Norwegian acts, and three Norwegian guides. They turned what they read into nine steps, each with a checklist and references to the exact law.
The steps run from the first to the last. Classify the project and name who is responsible. Find the lawful basis, and either consent or a legal dispensation from confidentiality. Get ethics approval before anyone touches a record. Sign data agreements. Set up security and privacy controls. Keep only the fields you need and check their quality. Analyze inside the secure room, and this step applies when the work involves AI or algorithms. Audit. At the end, delete or anonymize, and let only checked, non-identifying results out.
One caution sits inside the steps. Consent under Norwegian health research law is not the same as consent under the EU data protection rules, and the two must be handled side by side.
The authors say the same nine steps can be adapted to other EU and EEA countries. The first task there is to map who handles ethics review, access permits, secure processing and oversight. In the Netherlands, for example, they name ethics committees and two secure analysis environments, and note the national access body is still being set up.
The study cannot tell you the rules where you live. The guide is built on Norwegian and EU law, and the authors say it can be adapted to other EU and EEA countries. It is orientation, not legal advice; the authors say it cannot replace advice on your own case. And the rules are still arriving: the EU regulation is being phased in, and Norway's secure processing environment does not yet exist.
What to look for where you live is whether a public body must approve requests to reuse health records, and whether your consent is asked for or an ethics committee can waive it.
What this means for you
Where you live, this study cannot tell you what the law requires, since it rests on Norwegian and European rules and says only that other countries would need to adapt it. What is worth watching for is whether a public body must approve requests to reuse health records, and whether your consent is asked for or an ethics committee can waive it.
Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2
Who paid: The study was supported by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology (project code 30233), and the article says the funding bodies had no role in design, data collection, analysis, interpretation or writing.
Do not take this as professional medical advice.
The longer versionThe passages copied from the paper, the pictures, and every source with how much of it we read · 1334 words · about 7 minRead it →Close
A Nine-Step Path for Reusing Your Health Records, Written for Norway and the EU
The guideline says what permission, ethics review and secure rooms a project needs. It measures no outcomes, and it does not describe the rules where you live.
Consider the last time you signed a form at a clinic. Your file already holds your diagnoses, your prescriptions, your lab results. A researcher who wants to study those files for something other than your care is asking for a second use, and in Norway and the European Union that second use now has a written path to follow.
That path is the subject of a practice-oriented synthesis published in npj Digital Medicine by Dipendra Pant, Thomas Brox Røst, Harald Krüger, Pieter Jelle Toussaint and Øystein Nytrø, most of them at the Norwegian University of Science and Technology in Trondheim, with a health-lawyer co-author from a Norwegian hospital purchasing body. The work was paid for by a liaison committee between the Central Norway Regional Health Authority and the university, under project code 30233, and the authors declare no competing interests.
The team read sixteen regulatory documents, five of them EU or international and three of them Norwegian guidance documents, and turned them into a nine-step guideline with checklists, flowcharts and a table of who is responsible at each step. The steps run from classifying a project, through legal basis and consent, ethics approval, data-access agreements, security, data minimization, analysis and AI development, auditing, and finally publication, retention and deletion. No outcomes were measured, and no datasets were generated or analysed.
The size of the underlying estate is easy to underestimate. The article describes a study in which twenty EU member states, 74 percent of the bloc, report that between 80 and 100 percent of their populations can reach their own health records through official access services, and secondary use is still described as underused1. The article describes a study in which secondary use means using records beyond the purpose they were collected for, for research, quality improvement or policy planning, while direct patient care remains the primary use2.
The machinery has names worth learning. The article describes a study in which a Health Data Access Body, or HDAB, is the national authority that receives applications and issues data permits3. The article describes a study in which a Secure Processing Environment, or SPE, is a controlled technical room where approved work must happen, with role-based access, logging, monitoring and export controls, and only anonymized outputs may leave45. Norway already runs secure analysis platforms at its universities, and the article treats them as candidates that might be upgraded to full SPE status; the article says the SPE has not yet been implemented.
Two permissions sit side by side and do not merge. The article describes a study in which the access body does not replace national ethics committees, and a data permit is issued only after any required ethics approval exists6. The article describes a study in which consent is trickier still: Norwegian health research law allows broad or ethics-approved consent, while the EU data protection rule requires consent that is specific, explicit and revocable7. A project can therefore hold one kind of permission and still lack the other.
The trade-off is written into the design. The article describes a study in which researchers report that ethics approval varies between regions and takes a long time, which is a barrier for projects spread across several sites8. The article describes a study in which working inside a locked room adds paperwork, legal review and data-engineering effort, and can slow experimentation9. The article describes a study in which smaller teams without support, training and money risk falling behind large, well-resourced institutions10. The gain is an auditable record of who touched what; the cost is speed.
For the patient, the package includes rights. The article describes a study in which, under the European Health Data Space, people gain the ability to see who accessed their records, and the guideline lists a right to opt out of secondary use alongside rights of access, correction and portability1112. Those rights must be operationalized and documented, not merely announced12.
The rules are still arriving. The article describes a study in which both the health-data regulation and the EU artificial intelligence act are being phased in or adapted nationally, and interpretations may shift as practice matures13. The article describes a study in which, later this decade, access-body and secure-environment specifications are expected to be standardized across borders14. Other countries are told to look for functional equivalents rather than copies, since access bodies, ethics committees, registry custodians, statistical offices and secure research rooms may be spread across different institutions15.
Here is weeklyAI's reading. A guideline like this is a map of permissions, and maps of permissions tend to be read by the people who need permission and ignored by everyone else until a letter arrives. Readers in the United States, Canada and Latin America may file this under other people's bureaucracy. The expectation here is that the question will feel local only when a hospital, an insurer or a vendor proposes reusing records close to home. This reading would be wrong if people in those countries already hunt down their own national rules on health-data reuse, or if such proposals reliably trigger public questions about consent and secure handling. What can be done now is plain: ask your clinic or health ministry which body approves reuse of patient records where you live, whether an ethics review is required, and where the data must be processed, and keep the answer in writing.
A second reading concerns timing. Once access bodies, contracts and secure rooms are built into daily routines, turning them off becomes its own project. The expectation is that objections raised after such a platform opens will meet the reply that the infrastructure exists and cannot easily change. This reading would be wrong if health-data platforms in these countries have been shut down or redesigned within a few years of public objection. So raise questions while a reuse platform is being proposed, not after, and ask who has the power to order it stopped.
A third reading is about leverage. Some readers will not wait for an official explanation; they will request the record of who accessed their health data and under what permit, and compare what different institutions send back. That expectation fails if such requests are routinely refused or answered in unusable form. The guideline itself is explicit that it is built for project scoping and early orientation, not as a substitute for case-specific legal or ethical advice16, which is the honest boundary of what a document like this can do for you.
The authors are candid about the edges. The method is a directed content analysis of sixteen documents plus expert consensus, not a sweep of every soft-law text, so some local or sector-specific obligations may be missing, and technical problems such as anonymization, model-generated data and incompatible record systems need measures beyond regulation. Structured external validation with researchers, regulators, patient groups and industry is only planned for future work, and the article says so plainly. The guideline has not been tested, and it has not been shown to speed approvals or reduce legal risk.
Here is what that leaves in your hands. The next time a hospital, a clinic or an app asks for your records, you now know the shape of the questions: who approves this, who reviewed it ethically, where will the data sit, and what can leave the room. None of those questions require a lawyer to ask. This reading would be wrong if the answer turns out to be that no such body, review or secure room exists in your country at all, which is itself worth knowing and worth writing down.
The clinic form is still in front of you. What it does not tell you is who, in your country, would have to say yes before anyone else could read the file behind it.
Where each piece of context comes from, and how much of it we read
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "The EU/EEA member states maintain extensive Electronic Health Records (EHR), with twenty EU member states (74%) reporting that 80–100% of their population can access their health records through the provided access services 2 . Yet secondary use remains underutilized 1 , 10 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Secondary use refers to the use of health records beyond the original collection purpose, such as research, quality improvement, and policy planning 3 , 7 , 25 . The primary use of health records is for direct patient care."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Under the EHDS, an HDAB is the designated national authority responsible for receiving and assessing secondary-use applications and issuing data access permits (EHDS Arts. 55 - 57 )."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "An SPE is a controlled technical environment in which approved secondary-use data processing must take place under defined technical and organizational safeguards ( EHDS Art. 73 )."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Inside such environments, users operate under strict technical and organizational controls and may export only non-personal, anonymized outputs in accordance with the conditions defined in the data permit. SPE operators must implement safeguards including role-based access control, logging, monitoring, and export control mechanisms."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "The HDAB does not supersede national ethics committees; ethical review remains national. Data permits are therefore issued only after any ethically required approvals have been obtained, ensuring complementary but clearly separated responsibilities."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Consent under the HRA is not equivalent to consent under GDPR. There is a nuance in that, the HRA allows broad or ethics-approved consent, while GDPR requires specific, explicit, and revocable consent 34 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "But researchers often report variation in ethical approval practices across regions, prolonged timelines 35 , and for multi-site projects, it can be a barrier."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Researchers may experience a compliance overhead (e.g., data permit application to HDAB, DPIA, legal review, data-engineering effort) if secure platforms restrict methodological flexibility, which can slow experimentation or innovation."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Without sufficient support, training, and funding, smaller research groups risk being disadvantaged compared to large, well-resourced institutions (e.g., in terms of compute, proprietary applications, domain experts) 19 , 25 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Under the EHDS, patients gain additional transparency regarding the right to view (e.g., patient portals or ‘MyHealth@EU’), know which entities accessed their records ( EHDS Arts. 3 - 8 , 11 ) 21 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Note individuals’ rights under the EHDS, including the right to opt-out of secondary use ( EHDS Art. 71 ) and the right of access, correction, and portability of electronic health data ( EHDS Arts. 3 - 9 ) are operationalized and documented."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "Currently, both regulations and infrastructure remain in flux. Regulations relevant to secondary use, particularly the EHDS and the AI act, are undergoing phased application or national adaptation, and some interpretations may evolve as regulatory practice matures."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "As ‘HealthData@EU’ is rolled out later this decade, national HDAB and SPE technical specifications and accreditation ( EHDS Art. 73(5) , 75 ) are expected to be standardized across borders 8 ."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "For the guideline transferability to the EU/EEA, they should be interpreted in terms of functional equivalence rather than exact institutional replication. In other EU/EEA countries, the HDAB, ethics approval, and SAE/SPE functions may be distributed across national access bodies, accredited ethics committees, registry custodians, statistical offices, or institutional secure research environments."
- Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2 - the article this story is about — the whole article — the passage: "The guideline is designed for project scoping, governance coordination, and early regulatory orientation, rather than as a substitute for case-specific legal or ethical advice."
Pant, D., Røst, T. B., Krüger, H. et al. (2026). Guideline for secondary use of health records within Norwegian and EU regulatory frameworks. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02784-2
Who paid: The study was supported by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology (project code 30233), and the article says the funding bodies had no role in design, data collection, analysis, interpretation or writing.
Do not take this as professional medical advice.
The findings of other studies mentioned here come from this document; those studies were not opened one by one.

